Benzinga | Aug 25, 2020 08:42AM EDT

CNS Provides FDA Update On Berubicin IND Filing; Anticipates Submitting IND And Initiating Clinical Trials In Early 2021

HOUSTON, Aug. 25, 2020 /PRNewswire/ --CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided an update on theCompany's plansfor its lead product candidate, Berubicin, which is being studied for the treatment of glioblastoma multiforme (GBM). The company has taken significant strides in designing Phase 2 clinical trials and anticipates submitting an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) this year and initiating clinical trials in early 2021. In preparing for the IND submission, CNS has focused on clinical trial design and implementation, as well as establishing the necessary manufacturing capabilities.